Novo Nordisk A/s

Johan Selmer

Lotte Bjerre Knudsen

Kristian Tage Hansen

Fritz Poulsen

Niels Tromholt

Use of medicament for life saving treatment of critically ill patients and method of treatment. The medicament comprises a GLP-1 compound which effectively controls the blood glucose level.

Use of GLP-1 compound for treatment of critically ill patients

Methods and uses for treatment of dyslipidemia comprising administration of a GLP-1 compound and another antidyslipidemic drug.

Combined use of a GLP-1 compound and another drug for treating dyslipidemia

Assay method using internal calibration to measure the amount of analyte

A diagnostic reagent for the detection in vivo of increased release of a fibrinolytic enzyme or increased fibrinolytic activity in the human or animal body comprises an antibody reactive with a fibrinolytic enzyme, or a biologically active fragment of the antibody, labelled with a substance which permits the detection in vivo of binding of the antibody to the fibrinolytic enzyme. In one embodiment, increased clearance of the antibody is provided by subsequent administration of the fibrinolytic enzyme with which the antibody is reactive. The fibrinolytic enzyme is preferably t-PA.

Growing community of inventors

Farum, Denmark

Johan Selmer